{"id":"NCT01153841","sponsor":"GlaxoSmithKline","briefTitle":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","officialTitle":"Primary Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, in Healthy Infants in Vietnam When Co-administered With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-17","primaryCompletion":"2011-07-26","completion":"2011-07-26","firstPosted":"2010-06-30","resultsPosted":"2017-02-27","lastUpdate":"2020-01-02"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Synflorix™( GSK1024850A)","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix hexa™","otherNames":[]}],"arms":[{"label":"Synflorix Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and reactogenicity of Synflorix™ (GSK 1024850A) given as a 3-dose primary immunization course when co-administered with Infanrix hexa™ vaccine at 2, 3 and 4 months of age in infants in Vietnam.","primaryOutcome":{"measure":"Number of Subjects With Grade 3 Symptoms (Solicited and Unsolicited)","timeFrame":"Within the 31-day (Days 0-30) after each dose and across doses","effectByArm":[{"arm":"Synflorix+Infanrix Hexa Group","deltaMin":24,"sd":null},{"arm":"Infanrix Hexa Group","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":["23432812"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":199},"commonTop":["Irritability","Fever (Axillary)","Loss of appetite","Pain","Drowsiness"]}}